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This study formed part of an existing prospective cohort study describing the outcomes of 
treatment of patients accessing ART in Khayelitsha. Despite the reported favorable outcomes in 
terms of immunologic responses, the actual variations in patterns of and associations with 
immunologic response over time among adult patients accessing the community based 
antiretroviral treatment programme in Khayelitsha are largely unknown. 
The aim of the study 
The aim of this study focused on describing the patterns of and associations with immunologic 
response, together with some of their subsequent outcomes among adult patients accessing 
community based antiretroviral treatment programme in Khayelitsha. 
Study design and population 
The analysis of this study formed part of an existing prospective cohort study describing the 
outcomes of antiretroviral treatment of patients in Khayelitsha. The study population included 
patients accessing ART in Khayelitsha, Cape Town, South Africa. A sample size of 400 HIV 
positive ART na'ive patients was sufficiently powered for the analysis. The socio-demographic 
and clinical information required for the analysis was already captured, validated and entered in a 
database. Summary measures, logistic regressions, survival analysis, simple linear regression and 
population average models were used to make the analysis and report the findings. 
Findings 
There were 3373 patients included in the analysis, of which females constituted 70% (2358) of 











than females and their median ages were 36 years (IQR 40-41) and 31 years (IQR 27-36) 
respectively. The greatest proportion of patients was between 25-34 years (51.3%). 
The median baseline CD4 count increased from 92 celis/ill (IQR 38-149) to 282 cells/ill (IQR 
200-313) after one year of ART. The CD4 cell count increase was the highest in the first 6 
months-135 cells/ill (IQR 79-201) - and a more than 50% decline in this rate was observed in 
subsequent months. The greater increase was further achieved when viral load was suppressed at 
two time points and throughout the four years of follow up. 
The effects of baseline CD4 cell count on CD4 cell increase was the same at each time point 
across all baseline categories but also higher in the first year than the subsequent years. At the 
first six month time point, fewer gains in CD4 cell count were associated with older age, male 
gender and higher baseline CD4 cell count (P<0.05) and these were -35.5 (95% CI -56.7; -14.4), -
20.6 (95%CI -31; -10.2), and -14.5 (95% 8.1; 20.9) respectively. The gains in CD4 cell count at 
six months were associated with log 10 baseline viral load and the viral load at six months. These 
were 14.5 (95% CI 8.1; 20.9 and 25.8 (95%CI 11.240.4). 
The analysis of CD4 cell count changes beyond six months was done using three different 
models. The first one was inclusive of all patients, the second model included those suppressed at 
successive time points and the last model focused on patients with viral load suppression 
throughout all the follow up time points. In all these scenarios, fewer gains in CD4 cell count 
were commonly associated with lower baseline CD4 cell count, older age, high previous CD4 cell 
count and male gender (P<0.05). The CD4 cell count gains were associated with log 10 baseline 
viral load, the WHO clinical stage 4 and current viral load . In fact even more gains were 











The of discordant response was in the first twelve months. The factors 
the response is 
attained less than 50 of CD4 cell count from 
who 
Inn,rp<:.<:ln,o viral 
load to levels below 400 {,<,,"A'Ofrn were of an older and CD4 cell count. The 
in the age range than 44 years old had a CI 
a discordant rpCnA,r"lCP ,",,",,"\.J'<''' between the age 14-24. 
baseline CD4 cell count had the risk of 
95%CI to with baseline CD4 cell 
count 
The clinical nrr'frr"''''' to death between and non 12 
'HV"H"J was The CD4 cell count 12 was the variable 
associated with survival 
age and baseline markers of disease count, WHO and viral 
arc CD4 cell on ART in in the HIV 
programme. 
Males in this cohort had a lower baseline CD4 cell count and in CD4 
cell count to females. This has been attributed in 
response between males and ~"'U.""Uh' et al. In the cohort there was a 
CD4 recovery on ART: there was an initial recovery of CD4 cells in the first 6 
a more recovery. there was continued in CD4 











count values in the normal if continue ART with viral loads 
et aL 
CD4 were more in with load the 
up In with viral load at two successive 
in CD4 cell counts ,un, ... :u.".! with 
CD4 cell count on the rates CD4 cell over time 
the normal CD4 cell count similar to 
individuals. 
The discordant rP;;cnnln"" was low in our data. It is in fact less common in low 
income countries as cOlmoan:d to income countries et al. Discordant response 
in 12 months did not have an months on both CD4 cell count 
over ti me and outcome (death) in the HIV The of 
immune in lhe HIV programme are similar to those seen in from 
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CHAPTER 1 - INTRODUCTION 
1.1 Background 
This project arose out of a request from the Khayelitsha antiretroviral treatment (ART) 
programme, to assist in describing the CD4 count changes over time in the treated cohort 
of adult patients. This chapter provides the background to the project and the context in 
which it operates, as well as the human immunodeficiency syndrome (HIV) epidemic, 
and the role of CD4+ lymphocytes and the monitoring of CD4+ lymphocyte cell counts. 
1.1.1 Epidemiology and burden of HIV/AIDS 
1.1.1.1 The global HIV/AIDS epidemic 
According to UNAIDS (2006), it is estimated that a total of 39.5 million people were 
living with HIV in 2006 (2.6 million more than in 2004) (Fig 1). Also, the number of 
new infections in 2006 rose to 4.3 million in 2006 (400 000 more than in 2004). In 2006, 
2.6 million AIDS related deaths were recorded. 
Clearly, Sub-Saharan Africa remains the most affected region in the world. Equally 
important, not all African countries portray the same trend in terms of HIV prevalence 
and subsequent AIDS related mortalities. It is therefore important to take cognisance of 
the large differences in Sub-Saharan countries (Asamoah-Odei et al. 2004). In 2006, two 
thirds of all people living with HIV lived in the Sub-Saharan region (that is 24.7 million 
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Figure 1 : Adults and children estimated to be living with HIV/AIDS, 2006' 
According to the UNAIDS (2006) report, globally and in every region, more adult 
women (15 years or older) compared to males in the same age group are now living with 
HIV. At the same time, 17.7 million women are living with HIV, an apparent increase of 
over one million compared with 2004 estimates. The report also indicated an increase in 
access to treatment in recent years. It also highlighted a gain of two million life years 
since 2002 in low and middle income countries through the expanded provision of 
antiretroviral treatment. 
1.1.1.2 HIVjAIDS epidemic in South Africa 
In 2005, it was estimated that 5.5 million people of the South African population, 
including 240 000 children younger than 15 years, were living with HIV . 













































50 cells/!-tl was 55% (Coetzee et al. 2004). secondary by Van ",-,UL,,"JLU et 
(2007) the same data used Loerzee et al. (2004) years earlier, showed an 
baseline CD4 cell count and proportion Dallenrs with baseline CD4 
count which were 87 cellshtl (IQR 35146) and respectively. 
"~..,,, .. u Activity (2006) was also the ART ",-,aJlH1J::, up 
between 2002 and had a significant .HUL''''''' on the baseline 
count. baseline CD4 cell count increased from 48 to 105 cells/"",l 
in . cell count ...... u,,"'''_u an increase in enrollment of 
acc:essm,g treatment with immune (The Western 
Monitoring Report, 2006). 
reported immunologic reSDO]tlSes. actual variations 
with HU;UIUHUIUJ;:;l'v response over all1'JllJ::, adult 
community based antlfelfmina treatment programme Khayelitsha are not ITTl",,,,Tl 
HIV/AiDS and the immune system 
immune system is of a complex network of independent that 
work U .... L'vllU the body "F.'UU'" fungal, parasitic and viral 
UH .... "'.~\Jl.'" and from the tumor cells 2005). 
(2002) human defense infections to surface 
innate adaptive (or acquired) responses. In so as HIV 
the author ;:)uF=,J::, .... ",.;:) that the or 
takes the center When HIV llU'.v.OI a ceU, mechanisms 
5 
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to ""HJUUU et al. HIV attacks specific cells of unmune 
over and multiplies. other words, infected 
with HIV, a T-cell oecomj~S an HIV-replicating (Engenderhealth 2005). 
causes cell to As cells aecreases. 
person's system De(;OnleS increasingly compromised 
This subsequently destroys a substantial 




more suscetltible to 
of these thus cornpromlsHlg the 
",>"\"'a",,-,, (DiPentima et 2005). When the 
y,",,,-,uu,_,, to a threshold, infected 
infections that a 
able to fight (DiPentima et al. 2005). 
body 
\'<Ufi,\.<H\.,y immunity is known 
as AIDS can in severe life-threatening infections, some forms of cancer, and 
deterioration the nervous system (Engenderhealth 2005). 
These alSj~aSI~S are called opportunistic because take advantage of 
v ..... ,v .. '"".... immune system. opportunistic infections Crptococcal 
meningitis Pneumocytis pneumonia. 
HIV is transmitted through ...,"" .... &<., .. !".'-' of body fluids such as blood 
..-."' .. ".,,, and milk (Stine 
result an HIV HLJl'~"''',VU, not """"' .. ,,,.\" 
become infected with HIV may appear healthy 
appropriate health 
aL 2005). 
is sought) before 
7 
Although AIDS is purported to a 
has AIDS. Notably, adults who 
a substantial number of (usually 










When body's system against foreign invasion fails to function properly, the 
condition is AIDS (Acquired Immunodeficiency Syndrome) (Brown 1997). 
virus known for this condition is (Human Immunodeficiency Virus). 
HIV is a retrovirus, a of virus that stores its 1"-.""'''''''''"' information on a ""U<:C.''''-'''' 
molecule. a it creates a DNA of 
and becomes part of the infected cell's DNA (Engenderhealth 2005). 
The first cases AIDS infections were diagnosed 1981 in the 
individuals 














2.1 Literature on patterns of and associations with immunologic 
response 
2.1.1 Description of immunologic response 
Immune resoonse is basically described by the Heritage Dictionary 
English (2003) as an integrated bodily to an antigen, v"'~'vv .... u one 
mediated involving recOgmtllon U,",,",LLl\., <Ull.lV\.Iun,,, or 
previously "vU""UL<VU lymphocytes. Several literature citations refer to UHIU .... '", 
response. Virological response describes response alongside 
plasma levels below 400 or 1000 copies/ml ",""ll\.;""JeU\.;l and Tuboi, 2006). 
studies also to immunologic response cell count mcreases 
CD4 cell count or et 
Most studies to an mClrea~;e in CD4 cell count at least 50 cells/f-tl (within a 
specified period) or maintenance of CD4 cell counts a certain threshold 
200 cellsfl.tl) as replresentaW{e of the immunologic response to 
(Battegay et al. 2006). ,-,,",,,,,un.., use of the defi.f.ition response by some 
as cells/f-tl, no was attached to it 
(Loutfy et al. 2005). evaluated this definition models in 228 ART 
patients infected with viral load > 1400 copies/ml. 12 month CD4 cell 











that was a risk of progression for incremental 
increase in CD4 cell count response. They also established that patients with CD4 
cell/Ill were with a reduction the risk an rl.<JLh'-U\.,U 
event or death. then implies mcreases nrp,~tpr than 50 cells/ill were associated 
with even reductions in the risk of clinical outcomes. 
report CD4 count over 200 been associated 
with reduced of opportunistic diseases and favorable clinical outcomes (Battegay et 
al. is eX(:mJ)Jlllea by recommendations to discontinue primary secondary 
prophylaxis against a variety of pathogens when CD4 count has reached at 200 
cellS/ill for months et aL pathogens include Pneumocystis 
IYlnUN" and Mycobacterium avium '-'VAHIJJ'vA (MAC) HI.L'''''-''lVH"0. 
2.1.2 The effect of and the associated benefits 
hall of ~UU,U" .. immunodeficiency (HIV) infection is characterized the 




Antiretroviral therapy results in an increase in 
reconstitution the immune system (Kelleher et 
expected outcome treatment of patients 





improve CD4 count reSi)On:se (Graber et al. 2000). 
10 
et al. 2006). 
cells the functional 
Autran et at 
with highly 










receiving highly antiretroviral therapy (HAART) there is 
evidence an initial rapid • .., ..... · .. ".".00 CD4 count in the to six months 
starting likely to be 
(Batte gay et 
a;:,,,·v,,,,,a ... ,u with redistribution 
ART associated with 
reauCII0flS in viral load and reductions in morbidity mortality from HIV 
UI.U-''''U'Ull'' (Smith et al. 2003; .... "' •.• '-'''' •. ,,'-'. and Tuboi, 2006 and et al. 2007). 
an estimated 10-25% P"LA"''''", starting ART at cell '"'u ..... n". 
cells affected by the reconstitution disease 
or reconstitution characterized by inflammatory reactions to 
previously asymptomatic pathogens et al. 2006). noted that most 
of IIHJIVU'" are manifested after the inception 




effects on the immune response from onset of therapy 
to immunologic in terms of an CD4 cell count 
beyond This becomes more when the which 
pUI."H"" are on ART is considered as (Smith et al. 2003; et al. 2006 and 
Battegay et 2006). 
The rate recovery P<>CllI'P·rI by CD4 count, at two starting 
treatment, is that at et aL Ill"""""",,,,, one study 











first two However, aforesaid study was reported as having limited statistical 
power in addition not aU of its L .... J'lJaUL'" were naIve. In a different 
Smith et al. (2003) also ULaH" •• U convincingly consistent """""1';'" in which individuals 
who U."HUj, ....... virological suppression had an increase in CD4 count 
starting HAART. 
at three 
study by Lawn et (2006), which not adjust the viral load the patients 
that within the two 
cells/~l had equivalent or 
ART, 
capacity 
with VU':''''l .. '.., CD4 counts < 50 
immunological recovery during weeks 
ART '-VIHIJ'l" va",,",Ull,,, CD4 cell counts. 
CD4 count gains ... uw''V'"''" .... ,'-' with CD4 counts during as 
Lawn et a1. (2006), it has been postulated that lower baseline 
count at initiation antiretroviral therapy longer treatment periods to reach the 
desired CD4 count level et al. 
As mentioned previously, most authors include the duration of treatment explaining 
immunologic 
determine 
Attempts been made to come up UH .. '","',ii' to 
"""J.U"-• ..., respO][lse at the course of 
example, Lawn et al. (2006) reported that the period 0 to 16 weeks 
For 
the ..... ""to"'t rate 
of recovery and was associated with baseline viral load. the same 
patients viral loads greater than 105 copies/ml greater count lllcreases 
than viral loads. to weeks, cell ra.(",'(,,,,,pru was 
reported to with The authors reported that 











was also reported as a strong independent of subsequent 
recovery. From the above examples, it can be noted that at different 
response is determined different et al. 2006). 
A recent study in a income setting by Mocroft et al. (2007) showed that CD4 cell 
count in with undetectable viral load can rise to levels similar to healthy 
individuals. The authors also noted that ."",,, .... ,,,, who start ART with baseline CD4 cell 
count above 350 reach normal levels of CD4 cell count than those with 
lower baseline CD4 cell count. The authors concluded reporting the !-IV""'V"" of 
attaining normal CD4 cell counts in all patients regardless of their baseline CD4 cell 
count provided the viral load is kept below detectable levels. 
in sub-Saharan Africa start ART with advanced disease Although most of 
et al. 2006) the by Mocroft and colleagues clearly demonstrate the possibility of 
immunological recovery in all patients. 
2.1.4 Factors tbat affect immune response 
Most of the work done in immunologic response has included analysis that to 
UU'HUllV"V)I;''- response in terms of several socio-demographic and clinical factors. 
Such factors have become variables which have been described in literature as predictors 
of immunologic response (Lawn et al. 2006)~ These factors have been modeled as 
independent variables in explaining response and tested for signiticancce. 
For example, in one of these studies, Lawn et al. noted that the failure to attain 
200 was found to be associated with older age and lower baseline viral 











In one Swiss study, Battegay et al. (2006) noted that not all patients receiving 
antiretroviral therapy attained complete recovery of CD4 count despite continuous 
suppression of plasma viral load. These findings perhaps suggested that there are several 
other factors which come into play other than excellently suppressed plasma viral load 
which determine complete recovery of CD4 cell count. These factors may for example 
include age, baseline CD4 cell count, WHO clinical category, sex and the plasma viral 
load (Lawn et al. 2006). 
On the contrary, seemingly implicating poorly suppressed plasma viral load, Battegay et 
al. (2006) agreed with both Hansjee et al. (2004) and Douek et al. (2003). They all 
suggested that poorly suppressed HIV-l replication is a major factor impeding the 
recovery of CD4 cells, leading to increased virus-related cell death and apoptosis. In 
their concluding remarks, Battegay et al. (2006) noted that entirely suppressed plasma 
HTV-l RNA is not a definite prerequisite for an increase or stabilization of CD4 cell 
count. 
HIV-l-infected patients with good virological responses and continuous plasma HIV-l 
RNA levels below 1000 copies per mL, older age, long duration of HIV infection and 
lower CD4 cell count at baseline represented important risk factors for maintaining lower 
CD4 count (Kauffmann et al. 2002 and Kauffmann et al. 2005). 
A study investigating the continued CD4 cell count increases in HIV -infected adults 
experiencing four years of viral suppression on antiretroviral therapy (Hunt et al. 2003) 











months to four years included lower pre-therapy CD4 cell count, young age, female sex 
and infrequent lower-level viremia sustained undetectable 
The findings of the above does not attempt to underplay the fact that gains in CD4 
cell counts still occur in older age but at a slower rate than the younger age. This was 
illustrated by Douek et al. The increases which still occur in older age were said 
to be associated with increasing thymic output (Douek et al. 1998). In the thymus is 
the site of the production and of lymphocyte T cells T-cell 
The authors indicate that the adult can 
contribute to immune recom>tlhltlcm HAART. In conclusion, highlighted 
that although the thymic 
into late adulthood. In fact 
declines with age, a substantial is maintained 
the early days of HIV infection, function 
decreases and that can be measured in the peripheral blood and lymphoid tissues (Douek 
et al. 1998). 
This limits its to nrAfl1l1'" cells in the early days of HAART 
As, HAART .. "".t1nl1"c the viral load particles decreases and the recovers 
some of its functions to aid immune restoration (Pido-Iopez et al. 2003). The increase in 
thymic function was Douek et aL (1998) to be associated with increases in 
CD4 T cell numbers in during the course of HAART. This 
"Alf''''U'''' some of the 
With reference to 
study by Giordano and 
in the CD4 cell count over time, 
the above were consistent with U'''~U'E,'' of another 











suppressed patients on ART for six months to determine whether CD4 cell count 
response to virus suppression during highly active antiretroviral therapy differs according 
to sex or race/ethnicity. Their findings were that women had greater CD4 cell count 
increases as compared to men and race/ethnicity was not a factor. 
Explaining their findings, Giordano and colleagues reported that women repopulate their 
peripheral CD4 cells in response to virus suppression more quickly than men do. The 
authors suggested that women may have increased peripheral redistribution of memory 
CD4 cells from lymphoid tissue in response to viral suppression as a result of the effect 
of ART. To explain the long run gains of CD4 cell count increases which are more 
apparent in females than males, the authors also suggested that women may have more 
thymic output of na"ive CD4 cells in response to HAART compared to men. 
Also explaining the differences in CD4 response by gender, Giordano et al. (2003) cited 
pharmacokinetic differences between males and females probably also aligned to 
differences in physiological metabolic processes in the body. They suggested that these 
differences may result in women having higher antiretroviral drug levels, which 
subsequently lead to viral suppression and greater increases in CD4 cell count. 
Gains in CD4 cell count were not surprisingly also associated with the AIDS clinical 
stage. The HAART-induced normalization of thymic output during the immune 
reconstitution results in larger increases in CD4 cell count in patients with more advanced 











before treatment. In order to readapt towards normal cell levels, there is stimulation of 
prC,(!ulctlcm of more cells 
2.1.5 Immuue response Africa 
In Sub-Saharan n·,.,,> ... t<, with access to therapy frequently have 
advanced nOIJetlcllenc:y and may have diminished capacity for CD4 
count recovery et aL Most individuals enrolled in ARV programmes in 
sub-Saharan Africa have median CD4 cell count below 100 cells/~l (Lawn et aL 2006). 
The authors also that such I-Iat''-'''t'' have been rpn,()rt"f1 as attaining an elevated 
risk of morbidity and mortality before and after initiation of ARV therapy. 
The potential for immune recovery has been by Lawn et al. (2006) to be 
limited in patients with advanced immunodeficiency. They specifically 
noted that the for restoration of CD4 cell counts and CD4 functional responses 
during ART has been to be associated with nrf"_Tr,"'''IfT1 
Seemingly contradicting these u""UHEP, Hunt et al. that the immune 
system's capacity for CD4 T hm,,,t.,,,,,,tp restoration was not limited low nr~'_tl1,pr'.n" 
CD4 counts. 
2.1.6 The effects of co-infections on the immune response 
There has not been a definite conclusion on whether some co-infections such as 
HIV/hepatitis C virus ( limit cell recovery whereas some appear to enhance 











In one study by Lincoln et al. in Australia, it was reported that 1""""-'''''' co-infected 
with HIV/HCV appeared to have a poorer response to HAART in terms of CD4 count 
changes, with a CD4 count increase of 32 cells;'.d (95% CI less than HIV -only 
patients. These also found that co-infections with HBV or HCV were 
relatively common among the HIV-infected. In conclusion to these findings, they 
that outcomes HAART did not appear to be '''',"'PT''PI affected by 
HBV/HCV CO-ltntectlOn. llU,I""''"'U CD4 count responses in co-infected 
patients. 
Another study Atkinson et a1. (2002), involving 103 individuals of whom 35% of the 
patients were ,,",V"U"'''''',,",'' with HCV and 86.1 % of this nrr.nnrtulrt had acquired HIV by 
injecting found that HCV co-infection had no effect on CD4 response in 
antiretroviral-naive 1""'''-'''''' during the first year of therapy. In their regressional analysis 
they found that there was no :>'",'!lU.I""" difference in the uue,vuuv, peak or rate of CD4 
cell response, with to HCV serostatus. "5"HC;""'U. that for those individuals 
with CD4 count of <200 the likelihood of a CD4 count >200 cellS/ill at 1 
year was 51%. This demonstrates a high likelihood of favourable CD4 cell count 
response and minimal impairment of CD4 cell count "'''''''''<l,rPfl to the already mentioned 
study by Lincoln et a1. (2003). 
2.1.7 Factors theoretically known to hinder complete immune response 
There is also limited knowledge of the factors that determine CD4 cell responses and 
seem to on both the host and the virus V-"'''''1;;''J et a1. Theoretical factors 
known to U£>IV""'" complete recovery of CD4 count could range from increased 
viral pathoJ~enicilv to certain inherent host factors et al. 2006). In addition the 











suppressed plasma HIV-1 Ribonucleic acid (RNA). also su~;ge:st that such a 
scenario may further Im1pecle "''''Ule'''''''' recovery ofCD4 cell count. 
One good eX,imDle of such a case is seen in a Swiss study by Kaufmann et at (2005). 
They found that 36% of the 1""''''''''' on ART did not reach CD4 cell counts above 500 
cells/!!l after 5 years continuous of viral load to below 1000 
copies/ml and almost half of these had reached a plateau in their CD4 cell count 
(Kaufmann et aL 2005). 
2.1.8 Description of "Discordant or paradox" CD4 response 
Population-based studies have demonstrated that in a large proportion of patients 
antiretroviral therapy their CD4 increases appear to occur without apparent '"};UU''''U.''' 
reduction of viral an unusual behavior as "discordant or IJ'UUU'-'~ CD4 
response (Wood et al. The discordant CD4 response is not only associated with , 
increases in CD4 cell counts but scenarios can also arise where patients on antiretroviral 
therapy seem not to exhibit "U};~JU.'"U''' rise in CD4 cell counts despite viral suppression 
(Tuboi et a1. 2007). 
Other examples of discordances include n!>tlpnt<! on ART for long periods that experience 
persistently low CD4 cell counts undetectable viral load. With regard to the 
aforesaid example, at Chelsea and Westminster in London 
reviewed the records of over 1140 ,,<>tlpntc and found that after one year 16% failed to 
show an increase in CD4 cell counts above 50 suppressed viral loads 
et at 2005). some t'I<ltlpntc may achieve undetectable viral load (falling 











found 13% of over 300 people on treatment experienced substantial viral load 
as well as in CD4 cell counts (Maggiolo et al. 1999). 
2.1.9 Mechanisms of development of discordant CD4 cell count 
There seems to be no definite explanation to the mechanisms 
oe'll'el(J'pmlem of rli",,,,,,.rI,, .. ,t' CD4 cell count response (Tuboi et al. 
ael)enael11 on the interaction of a 
factors. linked possible explanations to the role of 
the 
The authors 
of viral and host 
inhibitor-based 
responses related to decrease HIV -associated T-cell apC)ptclsIS by HIV ..... ,.,t"'".,'" lflhIlJlt()r 
,.."",,.. ,,,,,,, in and possibly to the weakening of the prc)tellse inhibitor-resistant 
virus (Wood et al. 
"YAU,X~"';s reference to of a closely followed cohort of ART nai've Wood 
et al. that patients who exhibited discordant response in 
twelve months of ART had either a prior transient/gap of presumably 
undetectable viral load and/or partial suppression viral load to < 100 copies/ml. 
The same authors ,.",,.,A,.,,,,,£1 that these results sUl~2e:ste:d that viral suppression is the 
primary mechanism involved in discordant CD4 count increases. 
2.1.10 Research done on discordant CD4 cen count 
Graber et al. (2000) conducted a study on discordant outcomes 
inhibitor (PI) naive patients in a developed country setting. Part of his LUH.UH/'S" were that 
19% of the had significant CD4 cell count increases after six months of 
antiretroviral thp""'1"m in the absence of a significant viral load reduction. The authors had 











and VIV/<,l,-,Ql success as a decrease in HIV RNA viral load of more than 1 
copies/mI, after 6 months on treatment. 
These were consistent with other findings from several sources in which 
immunologic discordancy was reported to have occurred in 20 to 30% of 6 
months to 2 years after starting HAART et al. 2007). 
2.1.11 Research on discordant CD4 cell couut response specific to low income 
nations 
There are limited data on discordant responses in terms of the and its 
associated prognostic significance in treated in resource constrained 
countries 
of 
~ctlecJ1ter & Tuboi, 2006 and Tuboi et al. 2007). One first known of 
done in a low income resource reported a finding of overall 
response of 33.8% after six months 
of this study were vv>ulJ,un,1". ""J1UIJ1'-"'" 
of discordant UUJLUY"VJ'VFo;,'''' and 
et aL 2007). The 
to immunologic, virologic and Y'\f\J'L1',""",f\T\(jp,'C and also the same 
definition as used above for immune response and virological response. 
The Antiretroviral Therapy in Lower Income Countries Collaboration an 
"1J'''''''ct'',nVj<,n."u network of HIV/AlDS treatment programmes in Africa, Asia and South 
America r"n"rr,>t1 on the .u"yw~m •• y of discordant responses in 1916 ",,.p,,,,,,,,,, treatment-
naIve T"I"tipnt", seen in 15 ",",'¥vl'UIJ'UI". countries who initiated HAART between March 
1996 and April 2004. A total of 269 p,n,,,, .. ,., (14%) were virological reSIDorlde:rs and 











that the frequency of discordancy in low industrialized """'VIi'''' was .. ",n,("\rt~.rI to almost 
"HU,U'" to that of high income countries (Schechter 
Factors known to explain discordant response 
mentioned earlier on, there is scant information the pathogenesis of discordant 
"'''''"''V'''~''''''' which seems also to somehow on the interaction of a multitude of 
and treatment-related 2006). Blunted CD4 
suppression attributed to host 
particularly 2006; Piketty et aI. 2001; 
Moore et a1. 2006). It has been immune restoration is 
dependent on thymus activity, (Schechter & Tuboi, 
Thus older age has been as a immunOlogic discordancy. 
Renaud et a1. (1999) reported that rates decrease in CD4+ cell counts before 
therapy initiation are 
CD4+ cell decrease are 
therapy is instituted. 
recovery, whereas sharper slopes 
maximal subsequent cell distribution once 
therefore UHI>'U\_" that rate of CD4 cell count depletion after 
HIV lnlleC[lOn is "'''' ...... n''',. • ..,''' is TMn/"\rt"nt (Tuboi et a1. 2007). 
Other T,>",tr\,." associated 
include toxicity, and 
tenofovir/didanosine Tuboi, 2006). The ''''U,HU'" 
use of zidovudine or y.y, .. ",,,u.,,, as part of the antiretroviral .",<"uu,..,,,, concurrent use 











infections, such as all associated with suboptimal count 
responses despite suppression replication. Adherence to therapy may also 
influence the occurrence discordant responses (Moore et al. 2006). In this study the 
authors reported that suboptimal 
virological and immunological only reSpOltlSes. 
& Tuboi, (2006) 
evaluating the impact 
reSDOlllses. On the other 
nT'Il''''?' ... ".".v""", receiving 
et al. (2006) reported the 
... " .... u .... '" of discordant responses 3-9 months 
2.1.13 The association of discordant response 
was found to be associated both 
of published controlled 
incidence of rl1CIY"'rI 
....... ~,u,," .. v ... observational studies 
v;:;".un.'"'''' One observational study by 
.... "'".V"''' .. ''VU h .. t'"",.~.1"1 regimen type and 
initiation. 
risk of clinical progression 
majority of published studies have ... "'LV ..... '"'''' that, comparison with complete 
discordant responses are associated with an 
,",U'"U""'U progression (Tuboi et al. 2007). The authors 
with increased risk of clinical 
et (2001), reported 
death or 
'O""'JLU<UU respOIlders at months experienced ,Hi;lUL''''U1IIUJ more L lu.,U'v-"' ... ·u .. uL5 events 
A study et aL (2005) reported that immunologic responders non-
responders) and responders (immunological non-responders) a 











greater death or new AIDS-defining event than complete respectively, 
had a up period of months involving 2100 antiretroviral experienced 
and of these un .... u.,!".", it can noted that 
responses are 
.",,,,,",v •• u,,.,,, in both 
risk of progression 
""'VI"''"'''' and low industrialized "''''Vll>:>, 
concordant 
contrary, Wood et (2002) seemed to absence differences in 
to AIDS or between discordant CD4 responders concordant 
virologic/immunologic reported population Despite 
contradictions, et (2007) acknowledged that frequency of tacl:ors of and 
for response is the same for high income low mC:OIT1C 
(2000) noted discordant reSIPODlses in HIV RNA 
counts are common, agreed with et (2007) by suggesting that va, • ..,u,,,, with 
an immunologic response, or without a virologic reSIPOIlse, 
clinical progression than those without an immunologic response 
are at less 
months. 
The fact Graber et aL 2000 found that discordant was maintained at 
months in 56% of with an immunologic and those with a 
HVJlV!".''''' response that the combination of immunologic reS:DonS(~S 
to therapy over time is likely to be the predictor of (Gulick 
2000). 
present, is limited done in the Khayelitsha \.laL,aLl''''''''' investigating the 











CD4 cell count reS,DOlnse such as the discordant CD4 cell reSDOlrlSe n"""U1." first two 
two years and 
I-'U'~vH'''' undergoing 
remain largely 
years. The and associations with CD4 response 
the clinical of discordant CD4 cell responses 
antiretroviral the context of the Khayelitsha 




MSF clinical database 
CUllce:rmln,ll; CD4 response alone 




never been studied in the 
carrying out this research study is to help ~u",.uUJ. patterns of and 
effect of time """'v" ..... '" .. '" with immunologic response and to 
on count In some 
suppressed 
reSI)Om;;e (Wood et 
counts fail to increase 
load a phenomenon as 
It is 
of .... <ltt"' ... ," a!iSOCIatea with immunological reSpOlrlSe in the Khayelitsha cohort as 
for U1P'nt,TlI' patients at risk of blunted on the patterns of immunologic 
response cohort such as frequency of discordancy, the aSSOCllated 
clinical outcomes, and long-term anticipated reSDOnSt~S are important at a programme 











2.4 The study aim 
aims of study are to 
1. Describe ""nrpm of and associations immunologic CD4 reSPOlllse 
the "'''''''U,""Jl''' discordant immunologic response 
Explore the outcomes patients discordant immunologic 
2.4.1 specific objectives 
specific OOleCIl of are: 
1. describe the va.Jl,",,!!L population characteristics and HIV history 
To CD4 reStJOn:se to in Khayelitsha cohort over 
3. To explore baseline and time-varying ... "''''''''"'J, ...... ,,'''' with response 
4. explore the associations with CD4 response patients over time who remained 
virologicaly suppressed 
5. describe frequency of immunological discordant responses determinants 
including the baseline cell count which UH.,lU' .... " 
a. u...,~.'""UUiU:]:; the frequency at various durations on 
b. describing determinants this outcome 











CHAPTER 3 .. METHODS 
3.1 The study design 
The analysis study .LVLU .... 'U part of an ,",2U,:>"1I';::' prospective cohort study describing 
the outcomes of antnel:rmm3 treatment of patients in Khayelitsha 
3.2 study population 
study population accessing ART in Khayelitsha, Cape 
Town, South majority of these patients in Khayelitsha lived of 
low socio-economic status and transmission is predominantly heterosexual. 
were started on ART between May and end 2005, followed up until the 
end 2006. subjects were all HIV positive and ART naive and were years and 
older 
The first-line ART v;;:.",u~,u was mnrl~f'li of 
reverse transcriptase inhibitor 
failing line was ",",n!'lnr, 
(3TC) plus a non-
or nevirapine). The "v"'vu,-,-, 
(AZT) didanosine. Prior to 2004, some patients started on 
zidovudine 
All patients 
with CD4 counts< 200 daily coIltmmo:x:azole prophylaxis. 
3.3 Sample size sampling 
mentioned earlier on, the analysis formed part of an 
with more than 3000 positive patients already in 
prospective cohort study 
database. Despite what may 
seem as a "large enough" sample it was also """"ant,,, to 
powered. 
required 











80% were pv ... ",,,..tpri to have a CD4 counts 
between two and three (Smith et 2003). Postulating 75% of the 
would have a 50 change in CD4 count during same period, size 
was determined. 80% power to a between 80%, the 
size l"£'>lrnnnfo.hn using 357 veU,...,"L" as required analysis. 
Also mentioned on, response in about 
of V<>L1'-'11"" in low iHUU"LUUi nations. With a precision of 
confident that proportion immunologic discordancy lay in this 
At 20%: N=1.962 * 0.2 * (0.052) 
Or 
At 30%: '0.3*0.7/ == 323 
Therefore a ""1"""''-' size of 350 patients was required for subsequent 
The computed sample .::>1 .. <1.<"",' than the actual number of in the 
database. Thus, 
sample 
number of l-/o.Li...,"." to be used in analysis exc:ee(]eo the computed 
since all patients in the ULuvue,,,, were used in analysis. 
3.4 Measurement and data collection 
Trained 
laboratory 
load were collected at 
checked at start 
standardized procedures to prospectively clinical, 
The blood cell count and viral 
same time points. The CD4 and viral load were 











load data were obtained up to about 28 days at either side of scheduled visit. Structured 
clinical and laboratory records were maintained on all patients screened on entry to the 
ART programme. During screening and follow-up, some of the captured information 
included demographic details (such as age, sex and place of residence), attendance at 
clinic, weight, diagnoses of infections, prophylaxis and treatment, CD4 cell counts and 
HIV RNA levels, sputum smears and culture results for TB, WHO clinical stage and 
antiretroviral treatment history. 
3.5 Definitions of immunologic and virologic responses and clinical outcomes 
Immunologic response was initially defined as an increase in CD4 cell count from 
baseline of more than 50 cellshtl. For the purposes of identifying patients with discordant 
immunologic response: these were patients who achieved virological suppression «400 
copies/ml) and at the same time failed to attain an increase of 50 cells/!-tl of CD4 cell 
count after 12 months of ART. AIDS defining events were defined according to the 
WHO staging system. 
3.6 Data management, statistical analysis and inclusion and exclusion criteria 
The data (both clinical and sociodemographic data) had already been entered in the 
database and this process was validated. 
The sociodemographic and clinical description of patient population at baseline was 
done using descriptive measures (measures of central tendency & dispersion). These 
included means, medians, standard deviations, ranges and the inter-quartile range. 











variables. Thus, was upon analysis the population 
variables (such as age, HIV load, CD4 count) categorical 
(such as and WHO stage). as 
period which patients had been HIV positive and average for which 
had been on ART. 
In order to show CD4 response to the Khayelitsha over were 
to show frequency distribution absolute blood CD4 counts at 6 
months, months, months, 36 months, and 48 months. Blood cell counts 
respOJlse during ART was expressed as the mean or median change in cell count 
measured in ceUsf!.tl together with the corresponding standard deviation or inter-quartile 
range. CD4 count changes were measured from uu","u .. ..." at 6 monthly intervals 
the 48 th months. rates of _ ...... ,...,_ were determined for all patients, followed by 
patients with suppressed viral load at su(:ce!;;snle time points and in with 
suppressed throughout the follow up until the CD4 count measure. 
Linear models, incorporating population average were used to 
CD4 cell _ .. _ .. ,..,_ beyond six months stratified time the inception of to 48 
monthS. The ""al'''''''''''''« the effect time on response, 
into account repeated measurements. Time effects on CD4 count vl .... "E;" were 
considered individuals with UU"'''lH'v CD4 cell count than 200 cells/ill in to 
according to protocol. The analysis was 
also adjusted for effect of initial ~v ... uu,,'u 
t It does not take into account the population distribution. 
30 










count. Discordant response was added as one the exposure variables to establish its 
UH~'"'''' on CD4 cell count change controlling everything 
each per:son contributed more than one models are adjusted 
autoregressive covariance HUL'U1\. was imposed on the 
to model, 
intra-individual homogeneity. 
data to account 
the 
frequency of 
the __ ~ ... ,.., variability of cell count over time. the 
count changes at months were linear 
discordance response was determined by subtracting the 
count from cell count after one year, after two years, after 
and four years. During each follow up point, the net CD4 cell count 
was below 50 cells/~1 and the plasma load was 400 copies/ml. The 
determinants discordant response in the first of ART were by '~ .... '~"'_ 
regression. The response variable was a variable describing those patients 
to attain an increase of CD4 greater than cells/~l whilst remaining virologically 
Survival analysis was used to access the relationship discordant response in first 
year the sU!)sequlem survival beyond 12 months and the • ...,,,,, .... ,, were plotted on 
Kaplan model was used to access survival 
in patients discordant V"~JV!J'''V. Model .a~,uv,:,.n.," was to identify influential 
observations and outliers in the models and no observations were identified to have a 











Analyses were performed using 9.0 Statistics/Data software 
(Copyright Stata 4905 Lakeway College Station, 
77845 
All database who were positive and were included in 
analysis. stage of the included information 
the computation. 
3.7 Ethical and legal considerations 
This was of a "'" .... ' ...... 'u project entitled 
Routine SurveiBance of HIV population in Khayelitsha". The ethics approval 
this was obtained from 
v,-""u'"",,,,, at the University 
Research Ethics '-VAUUJ" .. ',,, of the Faculty Health 
Town. 
for the analysis was <>vt1'<>rot<>f1 from IJtnJ''''« database for same nl"r.1Pt't 
The names of patients were not included. Confidentiality of the patient was 
111aHH<U!1~,U at all times analysis. 
Reporting of the results 
will be rpn,,... .. t,·rI to all major ., .... n""'''-"''' .... '''.". These include nh1<f'r<:11hl of Cape 
Department of Public Health, Medecins Sans Frontieres (MSF), and The 











CHAPTER 4 .. RESULTS 
4.1 Descriptive analysis of the study 
section includes the description the 
undergoing community ART in Khayelitsha. 
4.1.1 The population baseline characteristics 
of 
At time anal ysis, total number of treatment adult undergoing 
ART captured the study database was of which and males 
constituted 69.9% (2358) and 30.1 % (1015) respectively (Table 1). The median was 
years (IQR, The ages and were (IQR 31-41) and 
(IQR 27-36) respectively. The sum 
(P:::';O.OOl) l-r-rprpn,~p between the ... """"''' 
was catc;Qonz<::d into 
included patients with between 14-24 
test showed that 
females. 
~UL'~"'l4U"'IU analysis. 
was a ""5"U'-L''''UU 
age 
sub Crt"f'\I1t'\'" 
44 years. largest proportion the patients (50.9%) was 
years and more 
range 25-34 
The median baseline cell count was 87 cells/ill (IQR 35-146). '"'u ..... ,,'" had higher 
uu"'''', ... ''' CD4 cell counts 
cell counts within 
20.8% and 
1 copies/ml (IQR 4.59-5.57). 
(P<O.OOl) (Table 1). The proportion patients with 
50-99, 100-149 and than 150 cells/ill were 
respectively. The median u",,,vU"''V 10glO viral 
the time 
33 
























Table 1. The baseline characteristics of the patients included in the "' .... n"." 
Characteristics N(%) Median (IQR) P-value 
Age (years) 
Ali" 3373 (100%) 32 (28-38) 
Females 2358 (69.9%) 31(27-36) 
Males 1015 (30.1%) 36 (31-41) P<O.Ol' 
14-24 345 (10.2%) 
25-34 1717 (50.9%) 
35-44 980 (29.]%) 
2:44 331(9.81 %) 
Baseline CD4 cell count (cells/~) 
All 3282 (97.3%) 87 (35-146) 
Males 989 (29.2%) 74 (30-139) 
Females 2293 (70.8%) 92 (39-149) p<o.m' 
::;49 1085 (33.1 %) 
50-99 743 (22.6%) 
100-149 683 (20,1%) 
2:150 771 (23.4%) 
<200 3106 (94.6%) 
;:::200 176 (5.36%) 
Baseline log10 viral load 
All 2945 (87.3%) 5.11 (4.59-5,57) 
0-4 230 (7.81%) 3.65 (1.99-4,00) 
4.1-5 1071 (36.4%) 4.6 (4.34-4.85) 
5.1-6 1403(47.6%) 5.44 (5.00-6.00) 
>6 24](8.81%) 6.25 (6.04-6.72) 
PriorTB4 
All 3373 (100%) 
Yes 1574 
No 1799 
AIDS def'ming illness 
All 3373 (100%) 
Yes 1406 (41.7%) 
No 1967 (58.3%) 
Year of diagnosis 
All 3291 (97.6%) 
Before 2000 274 (8.33%) 
2000-2002 1137 (34.6%) 
2003-2004 1361 (41.4%) 
2005-2006 519 (15.8%) 
Period under HAART (days) 
All 3373 (100%) 529 (339-529) 
"All" refers to the proportion of the total cohort of 3373 patients 
for whom data was available. percentages refer to the subset of OJa',"v"U~ with data for the 
parameter. 
2 Wilcoxon sum rank non parametric test on the 
3 Wilcoxon sum rank non test on the 
males and females. 
of median age between males and females. 
of median baseline CD4 cell count between 











Most the patients were diagnosed nPt"up,,· ... years 2003 and 2004 (41.4%) the 
smallest proportion of patients was diagnosed year 2000 (8.33%). The 11 ....... U"" 
period for which the patients were on HAART by the the analysis was 529 days 
339-529). 
Cutsem et al. (2007) rnnfnl£'T"''' a secondary of the vU'''UU HIV 
.. , .. ,un"" They 
that 59% the patients within two At the time 
initiation of ART a third of the were reported to on treatment. used 
survival analysis to the loss to up and From 
16.9% - 21.0) patients were after 5 years follow up. 
,,"' •. u .... ,...., loss to up as a year without a visit. definition, they reported a 
loss to follow up of CI 16.9 this proportion also includes IJ<UJ.",Ut" 
who died. 5 years, a cumulative proportion (95% - 14.7) had 
to second had been on treatment for 5 7/34 
(20.6% ) were on second 
4.2 Description of the response to over time 
This includes the of CD4 cell espom;e together with 












2: The frequency distribution of absolute blood CD4 cell counts at each of the ''''''''''W .. n time 
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Table 2 Changes in blood CD4 cell counts and plasma viral load during ART 
Baseline 6 months 12 months 18 months 24 months 30 months 36 months 42 months 48 months 
Virological response 
No, of patients 
No, (%) of patients with 
VL<400 
Absolute CD4 cell counts 
No, of patients 
(All) 
3282 
2260 2142 1431 931 
2457 (92,4) 1894 (8804) 1234 (86,2) 799 (85,8) 
2645 2151 1409 934 
526 339 190 139 
458 (87,1) 300 (8SA) 163(85,8) 122 (87,7) 
510 329 190 141 
Median (lQR) CD4 cell 
Count (cells/flI) 
87 (35-146) 233 (163-313) 282 (200-380) 323 (227-435) 369 (259-496) 405 (290-552) 457 (327-582) 435 (314-622) 476 (314-656) 
CD4 cell counl change 
No, of patientsl 2579 1977 1298 834 455 277 162 110 
Median (lQR) CD4 cell 
count change (cells/flO 
over six monthly 
intervals 
135 (79-201) 52 (-1-109) 48 (-8-111) 49 (-9-111) 39 (-18-117) 36 (-46-110) 23 (-59-100) 42 (-37-125) 
No, of patients (%) 
(Virologicaly suppressed 
at two time points') 
2272(88) 1579 (80) 1013 (78) 636 (76) 357 (78) 225 (81) 125 (77) 86 (78) 
Median (lQR) CD4 cell 
count change (cells/fll) 
over six monthly 
intervals 
137 (81-206) 56 (7-14) 54 (1-121) 54 (1-118) 46 (-13-121) 425 (-45-114) 30 (-54-110) 43 (-46-149) 
No, of patients (%) 
(Virologicaly suppressed 
throughout the follow up 
period) 
Median (lQR) CD4 cell 
count change (celiS/ill) 
over six monthly 
intervals 
53 50 45 48 51 49 47 
149 (103-225) 69,5 (10-131) 45 (-32-97) 71,5 (12-128) 53 (-32-106) 17 (-48-75) 6 (-68-88) 
48 
79 (-48-175) 
lThe number of patients refers to patients with available CD4 count data at two consecutive time points, Thus No, of patients at 6 months refers to patients with CD4 
cell count data at both baseline and at six months and so on, 
'These are successive time points, for example CD4 cell count change at 18 months would refer only to viral suppression at 18 and 12 months, 
4.2.1 The description of absolute blood CD4 ceil count over time 
Graphs in Figure 1 show the frequency distribution of absolute blood CD4 cell counts at 
each of the follow-up time points that is at baseline, 12 months, 24 months, 36 months 
and 48 months, demonstrating not only increasing absolute CD4 count over time, but also 











The virological response to was generally good as was ,",,,",,_,,,.,u by the that 
viral load was suppressed to less than 400 copies/ml more 86% of the patients at 
each follow-up time points 2) one year treatment. 
Although proportion of patients with CD4 counts less than 200 was 
94.2% at baseline proportion decreased to 
months and 48 months of ART 
after months 
treatment. 
decreased to 12.4%, and respectively 1). 
proportion 
median blood CD4 cell 
count from a level of cellsf!,d (lOR 41-149) at to 
cells/lkl (lOR 199-379) one year therapy (Table median ... ,-,,",,,no.,", 
CD4 cell count continued to rise throughout the years of follow-up. 
4.2.2 The rates of CD4 count increases at each of the follow up time points 
The rate the CD4 count increase in the six months exceeded rates of 
preceding follow time at 12, 30,36, 48 months (Table 2, 3). 
same applied to the 12 months intervals rates which were characterized by 
higher rates in the year than subsequent 
up at 
cell count were a~H"V"L similar. 
~ Results not shown 
39 
30, 
1-1 ..... '.,,"'.,,"'.. when comparing the 
















6 monthly 125 -
intervals 





Time of ART (months) 
No. 2579 1977 1298 834 455 277 162 110 
The number of patients to patients with available CD4 count data at two 
time points. Thus No. of patients at 6 months to patients with 
count data at both baseline and at months and so on. 
pattern of count increases was divided into two phases. The 
the fast/rapid phase of the blood CD4 cell count (that is, 
over (lOR the ",'-'\._vuu phase, 
at months was mainly 
constituted by a phaseJmedian::: .1 cellshtl per U1L'11<1'''' period. 
baseline time associations of CD4 response 
The analysis section included describing the count on 
CD4 cell change and this was stratification. was then another 
of four first on the cell count 











'"'uu,u!".,~" at the months of The other three models i1;:':l'C~~)cu the un".., .... ", and 
associations of CD4 cell count beyond months. 
three focused on CD4 cell count _LL'~"",_ beyond first six U")'l1<>'" 
during the 48 month fonow 
patients, any 
at two \AJl"''''''.uu 
to their 
time points 
48 months fonow up 
Each of om:erent models included 1) all 
status, 2) fJ"""'''''' with nnl'p<::."pn viraemia 
3) patients with suppressed viral load throughout 
The 6 months had a "",valnl,,,, model the baseline characteristics were 
highly ... "",,,,, .. ,,,, .... CD4 cell "' ....... 0'" in the 
strength 
measurements are 
intra-individual association weakens as 
months. 
cell count 
at durations on the autoregressive covariance 
matrix was Each vaLl.""u has more one CD4 count measurement 
time points included in analysis. analysis UH"."'''''' adjustments 
repeated measurements of counts. each person could contribute more than 
one value to model, the models were adjusted intra-individual "~A"~J",_"'_" 
The analysis was adjusted previous cell count categc)rv 
4.3.1 The of baseline CD4 cell count on the rates of CD4 increases 
baseline CD4 count, the rates of CD4 lllcreases were When stratified 
highest at ... 4<"" .... 4>.> follow point in the UU",",Ull'-' category cells/)!I to 
higher va""" .. ,,", ~'4'_''''~' (P<O.Ol). 
After 36 months, patients 
significant in CD4 cell count. 
declined over time. (Table 3, 











Table 3. The median CD4 cell count increase in the preceding 12 months stratified baseline CD4 
Baseline CD4 count (ceUs/p.I) <50 50-99 100-149 C!!150 
12 months 
Number 638 507 463 493 
Median Rate IQR 
] 97 (128-290) 189 (117-279) 182 (109-257) ]65 (85-272) 
( ceIlshLi/year) 
24 months 
Number 3]9 210 174 157 
Median Rate IQR 
] 08 (40-] 88) 75 (15-181) 75 (14-] 72) 104 (20-191) 
( cells/~l/year) 
36 months 
Number 133 67 56 42 
Median Rate IQR 
70 (8-159) 63 (-10-146) 90 (-6- ]79) 63 (-8] -129) 
(cells/~lIyear ) 
48 months 
62 25 25 ]2 
Figure 4: CD4 count changes stratified baseline CD4 cell count 
Median Rate ofCD4 cell count increases stratified by baseline CD4 cell 















Duration on ART 
(M o!1ths) 
4.3.2 Associations with CD4 cell 
patients 
Several factors were independently 
Baseline CD4 count 
category 
at the first six months of ART in aU 
with CD4 cell count changes 











suppressed viral at six months count and " ... ,,"'.u,'"' viral load. On 
was not associated with clinical hand, CD4 count _ .. _ ..... _ in the same 
and 
Notably, '"''''''''5''''' in CD4 cell count at H.\J,,, ... ,, rI,,,,,.-,,,,,,,,rI with mc:realSlIlLQ. 
instance, older than 44 years Q.allrlea fewer CD4 cells/!J-I than lJaL1."""<':> 
between years (95% Males gained 20.6 fewer cells/!J-I 
than .UJU'''U'"'''' (P<O.01; 95% CI -31.0; months of therapy. 
in CD4 cell counts aec:reasea with cell 
patients 
ceUsfr,ll (95% 
count to the lowest baseline category (Table 4). 
with lJ",;,'wi".'" CD4 cell count greater cells/!J-I had 14.3 
CI compared to those 
in the log 10 
(P<O.01). 
""'''v ... J,u......... with gains in 
..... "'n .. '" was associated with a 
were not suppressed. 
had less than 50 cells/!J-I at baseline (Table 4). 
u",,,,,,,,.u.,,,,, viral load was associated a of 14.5 
virological 
count (Table 4). 
of 25.8 more CD4 
43 
months was 
viral load at 










Table 4 Prediction of CD4 cell change at the first six months of ART in all patients" 
Variable Mean change 
(celis/fLO 




Baseline CD4 cell count 
(cells/l.l.l) 
Baseline viral load per one 
log increase 
PriorTBc 















































a Wald test computation which gave a combined P-value for the following variables: Age groups 
and Baseline CD4 cell count. The test prevents Type 1 error which can occurs when comparing 












b The non AIDS clinical stage was comprised of stages 1, 2 & 3. Stage 4 was the AIDS clinical stage. 
"The prior TB variable refered to the history ofTB infection before inception of ART. 
4.3.3 The prediction of CD4 cell change beyond six months of ART 
The following three models describe the patterns of CD4 cell count changes during the 48 
months of treatment excluding the first six months (Table 5, 6 and 7). Amongst the three 
models, as mentioned earlier on, the first model focused on describing the baseline and 
•• Predicted change in CD4 cell count changes was assessed using multivariable linear regression. The 
computation included 1961 patients. All listed predictors were included in the multivariable model, which 













with suppressed viraemia at 
model described the baseline and 
V< ... ..,11<.:> with continuously surmn~sst~d 
count """A".!",'" in all patients, second 
CD4 cell response " ..... v .... '" _ ••• ~ ... ,.., 
two consecutive time points. Lastly, 
association of CD4 cell resnOlnse 
load up until the time of each measurement. 
models exhibited similar ... <:ott", ... ", terms of baseline and 
change (Table 5, 6 and Of first model which toc:us{:a 
associations count beyond six months in all patients "<>"',"or'o 
that change was associated last CD4 cell count category, OJ"'''''''''''''' 
load, continuously suppressed baseline CD4 cell count (Table 
CD4 cell change was not "''''''V,",,'''''''U with follow up time points, ""'HllU""''''. 
and prior TB. 
same model, the gains CD4 count aec:reasea with increasing 
group greater than cellsf!:d than patients between 
(P<O.Ol) . 
... ".,,,v~ 15.8 fewer CD4 cells/~l than gains in CD4 cell count over 
"'-'l...,a"..., .... with increasing baseline count. It could be noted that relative to 
with baseline CD4 cell count cells/~l, the CD4 count gains 
from 13.1 fewer CD4 ceUs/~l in 50-90 cens/~l to 1.5 
more CD4 cells/~l in patients with count over 150 ceUs/~l (P<O.Ol) 











count with previous CD4 cell count than 500 
were """'V"'J''''~'U cellS/ill than those between 200 and 
It was· interesting that more CD4 cells were ~'UJ"\.-U 
viral load as compared to gains associated with 
over continuously suppressed viral load CD4 
count gain. Conversely, previously " .. L'IJ"~""'~u .... """-'\.-,, ........ ,..... with 
CD4 cell count change over time tt. Those with continuous suJ)pn~SS]lO viral load had a 
gain of more CD4 cells/ill than those without 
contrast to the model without restriction to with patients 
who suppressed viraemia at any two COIlse,cut points had In 
gains in CD4 cell count by age 
years gained 22.3 fewer CD4 c llS/ill 
ft Results not shown 
5 and 6) (P<O.02). Notably, patients older than 44 











Table 5 Prediction of CD4 cell count change beyond 6 months of ART in alll'<l.";;I1"~ 
Age 




35-44 -7.5 -19.1 4.1 
2:44 -15.2 -30.0 -0.4 
Sex 
Females Reference group 
Males -15.8 P<O.01 -23.0 -8.6 
Clioical stage 
Stages], 2 & 3b Reference group 
Stage 4 6.1 0.1 11.8 32.3 
Baseline CD4 cell count 
0-49 Reference group 
50-99 -13.1 -21.3 -4.9 
100-149 -10.9 P<0.01" -19.7 -2.1 
2:150 1.5 -9.1 12.1 
Time 
12 months Reference group 
24monlhs -3.7 -21.7 14.4 
36 months 6.0 P<0.16a -10.7 22.6 
48 months -2.6 -21.0 15.8 
Last CD4 cell count category 
200-349 Reference 




350-499 -11.3 -20.8 -1.8 
2:500 -35.3 -48.0 -22.6 
Baseline viral load per one log 4.5 P<O.01 0.3 8.6 
PrlorTB< 
No Reference group 
Yes -6.12 0.1 -12.45 0.21 
Continuously suppressed 
viral load 
No Reference group 
Yes 22.1 P<O.01 11.8 32.3 
a Wald lest computation which gave a combined P-value for the following variables: Age groups, Last CD4 cell count 
category, Baseline CD4 cell count & Time. The test prevents Type 1 error which can occur when comparing across 
catergories within groups . 
.. The non AIDS clinical stage comprised stages 1,2 & 3. Stage 4 was the AIDS clinical stage. 
C The prior TB variable referred to the history of TB infection before inception of ART. 
u Predicted CD4 cell count was assessed using a multivariate cross-sectional time-series model 
which incorporated a population estimator which also is the same as a random-effects p.dim~tt'1T 
regression. The computation included observations from 946 patients. The observation per 
(range 2-7). observations were not equally spaced and thus were 
estimation. Some had fewer than 2 observations, thus it was not possible to estimate correlations for those 











vLAJ,"v"'" stage v,,,_aH..v an important "'UH~LU' of CD4 count change 
the model included with suc:ce~;Sl,'e suppressed viraemia, whereas it was 





there was no restriction by 
at any two 
in CD4 count changes over time between 
status and the model where patients 
time 5 and 6). CD4 cell 
count "'IWell}::,'_'::' were approximately similar in both models by such as sex, 
" .. .:ova •• ", CD4 cell count (P<0.05). 
When the was restricted to patients with su,~ce~ssn'e virological lOpres:slO!O. the 
model indicated that gained 17.7 cellshtl than .'-'Ul<U'-''::'. 
clinical J"., ... ." ... ,u 8.2 more cells/!-tl than with no AIDS "" .. " ...... " .... stage 
(P=O.03). in CD4 count increased baseline cell count 
Every unit in log 10 v"""".u." load was associated with a 
CD4 cells/f,tl. variables TB and continuously suppressed viral load 
were not important predictors of CD4 cell ""'«UIE,'" over time 
lDDresse(J viral load. 
successive 
In the which load was throughout, prior history and 
up time were the only variables not associated with cell count over 

















Baseline CD4 cell COllnt 
(cell"/ .... O 
ThDe 
La"t CD4 cell count 
category 
Baseline viral load per 
one log Increase 
PriorTBc 
Cont:lnuously 

































































































n 'VVald test computation vvhich gave 1:1 corrtbined P-value f'or the follovving variables: Age groups, Last CD4 
ccB count category" Baseline CD4 ce]] count & ·]'''i.ITIe~ ~rhe test prevents ~rype 1 errors 'VVhen comparing 
across catergories vvithin groupsw 
b 'I-he non AII':>S clinical stage vvas comprised ot~ stages 110 2 & 3~ Stage 4 VV'as t.he AIDS clinical stage~ 
C The prior "1"")3 variable refered to the history ot" TJ3 infection bet'ore inception of All.'l ..... 
t'predicted CD4 cell count change vvas assessed using a multivariate cross-sectional tilDe-series 
regression model 'YI'hich incorporated population average estimator vvhich also is the same as 
random-effects esthnator in linear regression. The computation included 2394observations from 
826 patients. ~rhe average observation per group VV'as 3.1 range (2-7)~ During the cO.ITIputation", 
observations 'YI'ere not equally spaced and thus 62 patients ""ere o:rnitted iro.ITI the estiITlation~ 
Some patients had f'eVY"er than 2 observations thus it VV'as not possible to estiInate correlations ror 
those groups and consequently 626 patients omitted* -rhe previous viral load variable vvas dropped 











Table 7 Prediction of CD4 cell count change 
suppressed viralload§§ 




Baseline CD4 cell 
count (cells/,.d) 
TiIne 
Last CD4 cell count 
category 
Baseline viral load 



















































































n VVaId test COITlputation vvhich gave a coITlbined P-value for the follovving variables: Age 
groups, Last CD4 eel] count category, l3aseHne Cl=>4 cell count & TiITle. The test prevents 
Type 1 error vvhich can occur vvhen coITlparing across catergories vvithin groups. 
b The non Al]::>S clinical stage W'as cOITlprised of stages 1,2& 3. Stage 4 ""as the AII::>S 
clinical stage~ 
~rhe prior T]3 variable refered to the history OL TB inLection beLore inception of A1~T. 
§§ Predicted CD4 cell count was assessed a multivariate cross-sectional time-series regression model 
which incorporated a population average estimator which also is the same as a random-effects estimator in linear 
The included 2287 observations from 786 The average observation per 
group was 3.1 range (2-7). During the computation, observations were not equally spaced and thus 13 
patients were omitted from the estimation. Some had fewer than 2 observations thus it was not 











The variables sex, age, clinical stage, count and baseline count and 
load had approximately same count over as 
observed in other models above (Table 6 and 7). 
summary, in all the models '*., time CD4 count changes were 
commonly """,V\.-'lU ... ,,,, with age, sex, last cell count category and <-'""'"'.u.'" CD4 
cell count and 10 ua,~\.-L'H" viral CD4 cell decreased increasing 
cell count, except those with baseline CD4 counts above cellsf!,tl. 
The CD4 count increased log increase baseline viral load. cell 
count decreased increasing over suppression is be it at any 
two time points or LHIVUiI::.U'JUl the follow up period, baseline was an 
important predictor of CD4 count change over In for predicting CD4 
change n"""'lTUl six ULU'UUL" in all u,""'.U.", continuously was 
change over time last ,"l1l'U"lr,f>,","PI load nrm"",rr no 
follow up and TB were not aSSOCllate;d 
cell count '-'lU ... """,. initial no on CD4 count "''''AU}'.,''' at 
months and beyond six months. When discordant status was into the model as 
exposure it did not subsequent gains controlling for 
4.4 The patterns of and .. ""our""."""' ....... " with discordant ....... "' ....... reSipOlnse during ART 
This ;:'\;o\',UU'll describes the frequency discordant immune reS1DOIllses at each follow up 
measured from inception of ART its possible determinants. risk 
••• The first model included all without any regard to their viraemia status, second model included 
patients with suppressed viraemia at any two consecutive time and third model include with 
suppressed viral load out the 48 months follow up time 











discordant CD4 count reSOOlrlSe in oaltlelrlts with continuously ",",nT'""",,,,"i'1 VIraemIa 
was also subsequent survival beyond months and its associated 
by discordance reSpUlrlSe were determined. As defined earlier on, discordant 
immune referred to patients who a,,<uu~,u less than cellshtl lllClrea~;e of CD4 
cell count from baseline despite viral load to levels below 400 copies/mL 
4.4.1 The .-,.."' ..... ,""."'''' of discordant response in the cohort 
The t-rp,nll~'nt''' of immunologic discordant responses is shown Table 8 below. 
Table 8 Frequency of discordant response at each follow up time point 
Six months 12 months 24 months 36 months 48 months 
Total number of 
2281 2367 2367 2373 
patients 
Number¥ (%) 283 (11.9) 99 (4.16) 13 1 
with discordant 
Discordant response was determined from difference of the baseline CD4 cell count and the CD4 
cell count at each follow up time among who were Patients 
with discordant response would be those with less than 50 cellS/ill increase in CD4 cell count 
proportion patients discordant l";';:'IJVjU;:''';' was the "'''"L'''C (8.19 first 
six months ART 8). There was a reduction proportion the second 













factors of discordant immune response in the first of ART 
risk of immunologic discordant """"nAn were 
multivariate '~F', ... "L"" and the results are shown 9 below. 
included I-'''''v''''' with "'"1'.nl't>'''''''ri viraemia for the first twelve months 
was a 
of Hl1UIUUv,eVJ:,l\ .. 
(P<O.Ol). 
had a 
independently associated with discordant reSDOIIse. 
discordant increased with 
greater than 44 
ri,C''"'' ... ·f1<'1'nt response compared to "' ..... " ... " 
proportion of the patients with 
to an increase of greater than 50 cellS/ill 
were 4.70%, 7.11 %, and 11.0%. 
count was a risk factor independently associated 
a increasing risk with increasing VU.,C>..,L.LUV 
count was associated with 
ART. Patients with lower v~~_ ..... _ 
reSpOlrlSe compared to patients with 
baseline CD4 cell count < 
to attain an increase of greater than 50 














Table 9 Results of a mlogistic regression model predicting the risk of discordant response at 12 
months of ART. 
Variable Odd Ratio Pvalue 95% CI 
Age 




35-44 2.4 0.7 8.2 
::::44 4.3 1.2 15.4 
Sex 
Females Reference group 
Males 1.6 0.1 1.0 2.6 
Clinical stage 
Stages 1, 2 & 3b Reference group 
Stage 4 1.3 0.3 0.9 0.4 
Baseline CD4 cell 
count (celis/iiI) 
0-49 Reference group 
50-99 2.7 1.1 6.3 
JOO-149 4.0 P<O.Ol a 1.7 9.2 
::::150 6.8 3.0 15.7 
Baseline viral load 
per one log increase 
0.9 0.4 0.6 1.2 
PriorTBc 
No Reference group 
Yes 0.9 0.5 0.5 1.4 
a Wald test computation which gave a combined P-value for the following variables: Age groups and Baseline CD4 
cell count The test prevents Type 1 error which can occur when comparing across catergories within groups. 
b The non AIDS clinical stage (reference group) comprise stages 1,2& 3. Stage 4 was the AIDS clinical stage. 
C The prior TB variable referred to the history of TB infection before inception of ART. 
m The proportion of patients with discordant immune response in this cohort was 4.16% (see Table 8) after 











The patients with 
(Table 9) of discordant 
baseline categories. 
4.4.3 The subsequent 
non-discordant 
The ,-,Uj,,,,",, .. 
beyond 
example, at 2 
compared to 
constant throughout 
However, the multivariate 
CD4 cell count "",,,,,('\rt<.r1 
count and UU""HAJ'''' 
count greater than 150 cells/!-t1 had 
(OR, 5.34, 95%CI 1.93; 14.7) compared to lower 
...... ,." ..... ,.. patients with immune discordant res:pOJDSe 
discordant and non 
not in crude analysis 
the patients with non-discordant response had 
with discordant responses (and this proportion 
up period) had died (Fig 4). 
.. "'" .... ""'c'r'n model adjusted for baseline characteristics 
..... " ... \./" ....... survival was only associated with 
IUVIIUI" (P<O.01) (Table 10). """.l","'V' status at 
12 months was not mOlcplenclcnu "'I1TuiU'll after 
CD4 count. 
















Aaplan-ll'!euer curve showing the proportion of patients who died at a time beyond 12 
with discordant CD4 response compared with non discordant CD4 response 
Kaplan-Meier failure estimates, by discordant 
2 3 4 5 











Table 10 Results of a Cox Proportional Hazard model to estimate the risk of death beyond one year 
in all patients 
Variable Relative Risk Pvalue 95%CI 




35-44 1.19 0.25 5.69 
2:44 1.46 0.26 8.29 
Sex 
Females Reference group 
Males 1.49 0.35 0.64 3.43 
Clinical stage 
Stages 1, 2 & 3" Reference group 
Stage 4 0.75 0.48 0.34 1.67 
Baseline CD4 cell count 
( cells/fl.I) 
0-49 Reference group 
50-99 0.92 0.36 2.36 
100-149 0.30 0.73 0.06 1.48 
:;::150 1.43 0.34 5.97 
CD" Cell count 0.99 P<O.Ol 0.985 0.997 
Discordant response 
No Reference group 
Yes 0.83 0.79 0.21 3.29 
Baseline viral load per 
1.43 om 1.08 1.94 
one log increase 
PriorTBc 
No Reference group 
Yes 0.77 0.51 0.35 1.70 
• Wald test which gave a combined P-value for the following variables: Age group and Baseline CD4 cell 
count. The test prevents 1 error which can occur when comparing across within groups. 
b The non AIDS clinical stage comprise stages 1,2& 3. Stage 4 was the AlDS clinical stage. 
"The prior TB variable referred to the history of TB infection before inception of ART. 











This was of associations with CD4 '''''''!-IV"U''"''' 10 ~"Ll"'HL" 
a"'''''''''''Hl~ triple-drug antiretroviral therapy (ART) in Khayelitsha township 
Town, South analysis included 3373 ART naive 
up for up to four years three ART clinics in Khayelitsha. 
providing ART to HIV-infected people since 2001. 
Patterns of response 
-lUl.""'''U patients 
VUAU""-" have 
Males in this cohort had a lower median vu,,,,,,.u".,, cell count compared to 1...,1BU.'"",". 
The variability of cell count across cohort increased to 48 months 
on (Fig 3). In cohort was a biphasic pattern of CD4 ""","",u,,,,, on 
median count were in six 
compared to months. was an initial rapid recovery of CD4 
in the first 6 months followed by a more gradual Importantly there was 
continued in CD4 count throughout the 48 month period, "U~"~","LUJ'~ that patients 
may potentially improve to CD4 count values in the normal if continue ART 
with viral loads for sufficient 
U .. " .......... " accord with what is known about immunological recovery on The 
phases CD4 cell count recovery during ART previously been described to be 
divided into two parts. disease is associated with and 
activation promotes sequestration memory T cells 
lymphoid 
first three to 
(Autran et 1997). The suppression viral load during in the 
months 
lymphoid tissue and vU""U'Vll" in 
rapid l",""""UlU".lL",'U of 
cell death during this 
58 













et al. 1997). 
ofCD4 
(2003). In the early 
et 
is """"V""", ...... ",, with 
count is 
infection 
is more gradual 
regeneration in 
"""''"'U;U'lL'''' .... by work done 
..... u,."'UVU.Cll capacity 
reduced. This capacity to new cells in the 







aec:reases and the recovers some of to aid immune r",,,,rnr<.t, (Pido-
(1998) to et al. 2003). 
associated with mcreases 
thymic was reported 
CD4 T cell numbers during ART. r .. ,·,nl, ... r>f is slow 
due to the slow repopulation of naIve CD4 
2003). 
by the thymus (Hunt et aL 
Although our .LAU'''''''',,,,» 
year follow up 
sustained beyond 
that CD4 cell counts continued to ,,,C',r,,,,,,',,,, slowly over the 
question that 1"'"HUll'" is whether ,nC'r","'""',, can be 
response. Patients 
However, a study by Mocroft et al. (2007) 
load suppression 
patIents with 
50 copies per mI, 





11j;;,UUAj;;, increases also in 
shown 
with baseline CD4 










Commenting on these .... .., ..... "M'" 
maximum virological suppression on 
& Boulle (2007) said 
would eventually normal CD4 
counts including those with lower baseline CD4 count. 
Associations with CD4 .... "''''' ... ,'''" .. 
CD4 were more pronounced patIentS with suppression throughout 
follow up time, followed by patients with at two 
time I-/V',11'':>. 
six months, lower CD4 cell count were a"",u,-",u.I.,U older male 
and higher baseline CD4 count. Higher 
were also associated with baseline viral 
months. The u.,:>,,'vvj":n~,u with 
older male gender, lower baseline 
and not having a continuously "n ..... >r."" 
also associated with CD4 cell count 
Although rates of CD4 cell counts 
cell count at months 
and a SU['Dn:~SSf~a viral load at six 
from 6 to 48 were 
count 
viral load was 
beyond six months of therapy. 
subsequent 
ART, the cell count on the rates of CD4 cell over 
persisted. Patients with lower baseline CD4 cell count «50 cells/""l) had the greatest 




uu." ... nuI"" categories 
compared to those with higher baseline count 
There were rates CD4 cell counts increase 











Lawn et al. (2006) had "' .. ", ...... un'''''''I''''' in which they suggested that 
baseline CD4 cell count 
responders to ART. """""lJi"" 
were least likely to be _.",,~,..,._._. non-
had the greatest 
due to their 
rates CD4 cell count rise, however, 
to attain absolute CD4 cell count I!re.iter than 200 
cell counts (Lawn et 
Explaining the implication between the length of time to 200 
cells/ill gain in CD4 count and the rates of increase, Lawn et al. (2006) that 
prolonged periods below "safe" CD4 cell count of 200 cells/ill 
mClrea5;e was likely to be a strong marker 
months of ART. Equally important, 
diminished rates of CD4 
morbidity and mortality 
count at baseline is the prClgnostlc factor for AIDS and death tsatteg,lV et al. 
2006). These authors ... a .... ~". .... ~ !J""'''''''' who start ART with 
cells/ill were at 
The patterns of immune our study are comparable to a study et al. 
(2007). These authors studied normalization of CD4 cell count 
naive HIV positive patients suppression below 50 copies/ml. Their was 
different from ours we ................... viral suppression as a viral load below 400 
copies/m!. But similar to our found that the rate of CD4 cell count 
diminished with cART (combination antiretroviral 
in patients who start ART CD4 cell count. also "'"..ClVLll,,"1\,U 











patients had consistently current absolute CD4 cell counts compared to 
patients who would had started with a higher baseline cell count 
Viral load at va""'Hl1'" 
of CD4 cell count 
at months and beyond stood out to the main determinants 
The gains in CD4 cell count explained by baseline viral load 
were lower than the gains attained when viral load was suppressed (compared to those 
at any given time point. In et aL (2006) sug;ges~tea that 
there is a positive correlation between CD4 cell sequestration in the lymphoid and 
plasma load. 
presence replicating HIV in the body stimulates cell sequestration. in the 
first 
from 
lU\-' .. <1.1.:> suppresses viral load replication, promoting redistribution of cells 
lymphoid tissue the blood. The degree of initial CD4 due to this 
redistribution is likely to be related to the degree sequestration prior to which is 
in turn related to the starting viral load. months, however, the baseline load 
becomes less important and instead, continuously lnnrp<:"l:p{j viral load at any time 
point a determinant of CD4 This is likely to in a 
to suppressed viral load a of adequate adherence to 
Sequestration memory in HIV -infected untreated patients subsequent 
redistribution on ART may explain why patients with 
in cell count. These patients have higher 
,-"",vu"",., have more gains 
loads and thus greater immune 
activation and sequestration of memory cells. capacity for redistribution when the 











demonstrated by the findings our study, less gain in CD4 count was strongly 
with older age both at and beyond six 
of their study, et (2003) reported women 1'1""'"'''''' their 
CD4 cells in response to suppression more quickly than men do. Our 
study confirms the results study. The authors suggested that women may have 
peripheral redistribution 
to viral suppression as a 
memory CD4 cells 
the effect of 
lymphoid tissue in 
higher CD4 
suggested that 
"''''tJ'VU''''' to ART compared 
count of ART, 
women have more CD4 
to men. Another study was by et al. (2003) to 
respOllIse difference between women and men in patients who ""<:'"1"1'1 
the immunological 
virologically. The 





T -cells were observed in women than men. 
Giordano et al. (2003), 
CD4 response, 
males and 
et aJ. (2003) cited 
et al. (2003) cited 
suggested that 
may result in women accumulating higher drug levels, which 
lead to suppression and in CD4 cell count. 
women are more likely to viral load 












At months the proportion patients with 
despite a suppressed load) was 4.2%. percentage is 
20-30% (Tuboi et al. 
the proportion 
study was conducted in a similar ""',ft1"« to the researcn(~r 
than HU.'V'.'" which stood npn,>lPP 
2007). Lawn et al. (2006) reported "' .. ,........ findings 
was 7%. 
another ART in Guguletu, Cape Town, South Africa. The authors 
attributed reasons 
to our study too. 
differences to 
reasons included the fact that 
naive were also low rates 







of discordant response increased with increasing OJ ... " .... u,,, CD4 cell count and 
mc:rea,slfllQ: age. obtained "uu,u.... findings to a study done by Tuboi et al. 
(2007). This study included 3111 patients 
factors for discordant responses in resource limited 
...... , .. .n.vu the of discordant response with 




income nations. our study, 
our study defined discordance at 
and 
findings 
OJ ... '>..., .... ..., CD4 cell 
to the L"U"U~~~ of similar 
analysis ..... "., .. ", .... 
months. 
In explaining reasons why the discordant increases increasing 
baseline CD4 cell count, Tuboi et al. (2007) attributed it to the non linear nature of CD4 











categories. was ex(!m)Jhtled by fact that our in CD4 
months was CTr"."t.,r than higher baseline 
the 
count lower U"""Hl.'" categories the 
The of our that the risk discordant response with was 
with hypothesis that immune restoration is dependent on thymus 
activity which becomes dysfunctional with et al. 
age the thymus to 
load fail. 
during thus a impact on ART-induced CD4 T-cell reconstitution 
et al. 2000). 
Clinical outcomes 
months was only variable aSS'OC:IaH~O with subsequent The CD4 cell count at 
survival after one year ART. We found no un.u .. ".",-,..., in mortality 
between those who had discordant response at 
to our study, Wood et al. (2000) """",f'\rt.,rl absence 
those that did not. Similar 
progression to AIDS 
or death npt1L"p'>fl discordant CD4 responders (both immunologic and virologic) 
concordant virologic/immunologic responders. 
Our study mirrors .uH'.Ull~;" of studies reported CD4 cell count as a 
important predictor of survival as compared to viral load. example, a study by Piketty 
et (2001) which involved 150 HIV infected patients with discrepant and 











assess their clinical outcome. authors concluded that the CD4 cell was a 
over plasma HIV load 
immunOlogic and 
pn::(]H:Unlg clinical outcome I-'("~"'HL'" who do not full 
UVJ'V<:CJ ..... respcmse:s. Although we 
but no immune findings et al. (2001) are to our 
Similar to our uU~"",","" CD4 cell count stood out to be the only death 
as load, age "'UJ:U,,",'''. stage. 
strengths and limitations 
limitation of this arose from using population average LU>J'''''-'.lCl which 
not allow us to population distribution. we could not estimates 
measures of and random effects H'''''''''''''' could 
not used because we ... " ..... ...,."' .... CD4 cell count "'HU'''",,"',-, months 
absolute measurements. strength in our in the 
structure in our This was justified 
count over the 48 months up. Although our study was 
in some patients were during the of the 
correlation because they than two CD4 count measurements. 
limitation the study was the that in clinics' database suppressed 
was as a load below and not 50 
was a drawback 
patients with 
we not directly COlrnp.aI our study to 















The ""<'T""" of infection did not us information. TB infection ,","'LUA"", 
the was not positive patients on TB treatment when 
they start had higher UU""AUAV those patients that are HU''' ......... ' ... but 
not on treatment. We could not control of TB treatment 
The UA"JU'F;" of this study are the fact that it was £'",,,,,,',£' .. ,,,, a 
UVlIUV"",,,,LLV,"'" population. The ~u~' ... " were all ART-naIve and received "' ... n"' ... A .... triple 
A,",1',"'"''"'U with uniform follow-up Despite the fact that 
different sites, these located in Khayelitsha and followed 
.. u" .. ", ... protocols. study are likel y to to 
programmes in 
Implications 
What are implications of the findings results for the Khayelitsha and 
sub-Saharan Clinicians need to be aware the immune 
.. ...,,,,, .. , ........... ,,. inflammatory "unnr£> during the early The 
elOpmem of IRIS is <""",'VvJlU",'U count below 
50-100 per III and usual1y occurs h"t,,,,,,,,,,, 2-8 weeks the 
et aL 20(6). This is the same which most our n'lt,,,ntc start their 
Furthermore, the same low va"'''lU''' category is also associated higher gains 
in count. It is not to underplay the potential development of 
early weeks count in ART. 


















suppression is HH1CHH<lH.l,""U 
if feasible. ,-'''''v 'v. 
stage 
the Khayelitsha 
\""'J.)'UU.,,,, was low in our data. It is in fact less common in 
to income countries (Lawn et al. 2006). 
did not have an impact beyond 12 months on both 
outcome (death) in the Khayelitsha 
baseline CD4 counts despite their 
that patients who start ART with 
"VI.UU", so long as 
monitoring of viral 
.."1"',,,0.;:',, progression (CD4 
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